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ABSTRACT
Background    Surgery has been reported to suppress 
cell-mediated immunity; however, the detailed mecha-
nisms responsible for this remain unclear. This study 
determined the expression of lymphocyte activation 
gene 3 (LAG-3) and programmed cell death 1 (PD-1) in 
lymphocytes following surgery for gastric cancer.
Methods    LAG-3 and PD-1 expression on both CD4+ 
and CD8+ T cells obtained pre- and post-operatively 
from gastric cancer patients were evaluated by multi-
color flow cytometry.
Results    The total lymphocyte count decreased rapidly 
from preoperative levels, reaching a minimum on post-
operative day 1 and remaining significantly decreased on 
days 3 and 7. PD-1+CD4+ T cells significantly increased, 
reaching a maximum on postoperative day 1 and re-
maining significantly elevated on day 3. PD-1+CD8+ T 
cells significantly increased and reached a maximum on 
day 7 before returning to the preoperative level on day 
30. There were no statistically significant differences in 
the frequency of LAG-3+CD4+ or LAG-3+CD8+ T cells 
after surgery. There were significant positive correlations 
between PD-1 and LAG-3 expression on both CD4+ and 
CD8+ T cells. 
Conclusion    PD-1 and LAG-3 expression on both 
CD4+ and CD8+ T cells was up-regulated and might be 
related to impaired cell-mediated immunity after sur-
gery for gastric cancer. 
Key words    gastric cancer; lymphocyte activation gene 
3; programmed cell death 1; T-cell
Gastric cancer is one of the most common malignancies 
and ranks second among all cancer deaths worldwide.1 
Radical (R0) resection offers the best chance for a cure 
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because it involves the complete surgical removal of any 
residual cancer cells in the tumor bed. However, a sub-
stantial number of patients experience recurrence even 
after R0 resection because of the occurrence of micro-
metastasis. Therefore, Japanese gastric cancer treatment 
guidelines recommend adjuvant chemotherapy with 
TS-1 for stage II/III gastric cancer patients to control 
micrometastasis and prevent recurrence.2 This recom-
mendation is based on the results of the Adjuvant Che-
motherapy Trial of TS-1 for Gastric Cancer study, which 
showed a survival benefit with adjuvant chemotherapy 
after D2 gastrectomy compared with surgery alone for 
stage II/III gastric cancer patients.3  
 The immune response is also thought to control 
micrometastasis. Yokohama et al. demonstrated in a 
mouse model of human gastric cancer micrometastasis 
that spontaneous regression of isolated tumor cells in 
the regional lymph nodes occurred following removal of 
the primary tumor and that this appeared to be primar-
ily through natural killer (NK) cell mediated antitumor 
activity.4 However, surgical stress generally induces 
suppression of cell-mediated immunity that is harmful 
to patients with cancer because it may diminish their 
ability to prevent postoperative infections and tumor re-
currence.5–7 T cells are a critical component of cellular 
immunity that are involved in the recruitment and acti-
vation of effector cells and amplification of the specific 
immune response to pathogens and cancer cells. T cell 
dysfunctions are characterized by diminished cytokine 
production, impaired killing and hypoproliferation. 
Wichmann et al. demonstrated a significant decrease 
in cell numbers of lymphocyte subpopulations, such as 
helper T (Th) lymphocytes, cytotoxic T lymphocytes and 
NK cells.5 Brune et al. reported that interferon-gamma, 
tumor necrosis factor-alpha and interleukin-2 production 
by T cells decreases significantly after conventional cho-
lecystectomy.6 Decker et al. showed that surgical stress 
induces a shift in the Th1/Th2 balance toward Th2, sug-
gesting that cell-mediated immunity is downregulated 
and antibody-mediated immunity is upregulated after 
surgery.7 However, the detailed mechanisms responsible 
for T cell dysfunction after surgery remain unclear.
 Recently, several intrinsic factors, including lym-
phocyte-activation gene 3 (LAG-3) and programmed 
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cell death 1 (PD-1), have been recognized as negative 
regulatory proteins that block the expansion and sup-
press the effector function of antigen-specific CD8+ T 
cells.8–10 PD-1 (CD279) was identified as a gene that was 
upregulated in a T cell hybridoma undergoing apoptotic 
cell death.11 PD-1 is inducibly expressed on CD4+ T 
cells, CD8+ T cells, natural killer-like T cells, B cells 
and monocytes upon activation.11, 12 Recent studies have 
shown that PD-1 is highly expressed by CD8+ T cells 
during chronic lymphocytic choriomeningitis virus in-
fection and that the PD-1–PD-1 ligand (PD-L) pathway 
plays a major role in regulating T cell exhaustion during 
infection.13 Furthermore, several new studies suggest a 
role for the PD-1–PD-L pathway in the exhaustion of vi-
rus-specific CD8+ T cells during HIV infection. Several 
reports have shown that PD-1 expression is elevated on 
HIV-specific CD8+ T cells and that blocking the PD-1–
PD-L pathway leads to increased T cell proliferation 
and effector cytokine production.14–16 Previous work 
has shown that PD-L1 is upregulated in HIV infection.17 
Collectively, these observations suggest that the PD-1–
PD-L pathway may indeed be operating during chronic 
HIV infection.  
 LAG-3, a CD4+ homolog that binds to major histo-
compatibility complex class II,18 is expressed on acti-
vated T cells, NK cells, B cells and dendritic cells, plays 
an important but incompletely understood role in the 
function of these lymphocyte subsets.19–21 Recent stud-
ies have documented a role for LAG-3 in CD8+ T cell 
exhaustion during chronic viral infection22 and LAG-
3 negatively regulated the tumor-infiltrating NY-ESO-
1-specific CD8+ T cells in human ovarian cancer.23 De-
meure et al. reported that increased expression of LAG-
3 was found on tumor-infiltrating lymphocytes (TILs) 
isolated from human renal cell carcinomas and other 
tumors, such as melanomas and lymphomas.24 Impor-
tantly, LAG-3 is closely correlated with the dysfunction 
of T cells in patients with chronic viral infection 22 and 
cancer.23 
 Given the association between PD-1 and LAG-3 ex-
pression on CD4+ and CD8+ T cells and T cell dysfunc-
tion in HIV, HCV and cancer patients, it is likely that 
these might be related to suppression of cell-mediated 
immunity after surgery. The purpose of the current 
study was therefore to examine the expression of PD-1 
and LAG-3 on lymphocytes to determine the role of 
these molecules in the immune suppression that occurs 
after surgery for gastric cancer.  
      
MATERIALS AND METHODS
Patients 
This study enrolled 33 patients treated at Tottori Univer-
sity Hospital who had a pathological diagnosis of gastric 
adenocarcinoma. None of the patients received radio-
therapy, chemotherapy or other medical interventions 
before surgery. The clinicopathological characteristics of 
these patients, according to the Japanese Classification 
of Gastric Carcinoma25 are shown in Table 1. 
 The study protocol was approved by the Institutional 
Review Board at Tottori University Hospital. Informed 
consent for drawing of blood samples was obtained from 
all individuals.
 
Assessments
Leukocyte and lymphocyte counts, C-reactive protein 
(CRP) levels and PD-1 and LAG-3 expression on CD4+ 
and CD8+ T cells were determined before surgery and 
on postoperative days 1, 3, 7 and 30.
 
Preparation of peripheral blood mononuclear cells 
After informed consent was obtained, approximately 
40 mL of peripheral blood was drawn from the patients 
before surgery and on postoperative days 1, 3, 7 and 30. 
Blood samples were prepared by centrifugation over a 
Ficoll-Paque (Pharmacia, Uppsala, Sweden) density gra-
dient. 
 
Flow cytometry analysis
Fluorescence-activated cell sorting (FACS) analysis was 
performed using a FACS Calibur (Becton Dickinson, 
Franklin Lakes, NJ). The following antibodies were used 
to determine cell phenotype: anti-CD4-FITC (RPA-T4), 
anti-CD8-FITC (HIT8a), anti-PD-1-PE (EH12.1) (BD 
Pharmingen, Franklin Lakes, NJ), anti-LAG-3-PE (R&D 
Systems, Minneapolis, MN) and anti-CD3-PE-Cy5 
(UCHT1) (BD Pharmingen, Franklin Lakes, NJ). Fur-
thermore, the following antibodies were used for nega-
tive control: FITC mouse immunoglobulin G1 (IgG1), 
Table 1. Clinicopathological characteristics of the pa-
tients included in the current study
Age, mean (SD) [range], yr  66.7 (11.8) [55–79] 
Gender Male  26
 Female  7
Histopathology* Differentiated  15
 Undifferentiated  18
Depth of invasion† T1 (early)  19
 T2/T3/T4 (advanced) 14
Lymph node metastasis Absent  22
 Present  11
Stage Stage I/II  25
 Stage III/IV  8
* Differentiated, papillary or tubular adenocarcinoma; undiffer-
entiated, poorly differentiated or mucinous adenocarcinoma, or 
signet-ring cell carcinoma.
† T1, tumor has invaded lamina propria or submucosa; T2, tumor 
has invaded the muscularis propria or the subserosa; T3, pen-
etrating the serosa; T4, invading adjacent organs. 
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PE mouse IgG1, PE-Cy5 mouse IgG1 (clone MOPC-21; 
BD Pharmingen, Franklin Lakes, NJ) and goat IgG PE-
conjugated antibody (R&D Systems).
 
Statistical analysis 
Statistical differences between two groups were deter-
mined by paired t-test. The accepted level of significance 
was P < 0.05. The GraphPad Prism software (GraphPad 
Software, La Jolla, CA) was used for all statistical analy-
ses.  
   
RESULTS 
Absolute leukocyte and lymphocyte counts and 
CRP levels 
The total leukocyte count increased postoperatively 
and reached a maximum on day 1. Although it then de-
Fig. 1. Changes in total leukocyte count (a), serum concentration of C-reactive protein (CRP) (b) and total lymphocyte count (c) after sur-
gery. POD, postoperative day; Pre-op, preoperation.
Fig. 2. (a) The reaction of isotypic control to CD4+ T cells after 
surgery by FACS. (b) Representative results for PD-1 on CD4+ 
T cells in peripheral blood obtained from gastric cancer patients 
after surgery by FACS. (c) Changes in PD-1 expression on CD4+ 
T cells after surgery. POD, postoperative day; Pre-op, preopera-
tion.
Fig. 3. (a) The reaction of isotypic control to CD4+ T cells after 
surgery by FACS. (b) Representative results for LAG-3 on CD4+ 
T cells in peripheral blood obtained from gastric cancer patients 
after surgery by FACS. (c) Changes in LAG-3 expression on CD4+ 
T cells after surgery. POD, postoperative day; Pre-op, preopera-
tion.
creased, it was still significantly elevated on day 3 (Fig. 
1a). A significant increase in CRP levels was also ob-
served on postoperative days 1, 3 and 7, compared with 
preoperative values (Fig. 1b). In contrast, a rapid and sig-
nificant decrease in the total lymphocyte count was ob-
served on day 1 after surgery (Fig. 1c). The lymphocyte 
count reached a minimum on day 1 and then increased, 
but was still significantly lower than before surgery on 
days 3 and 7.
 
PD-1 and LAG-3 expression on CD4+ and CD8+ T 
cells 
The frequency of PD-1+CD4+ T cells significantly in-
creased postoperatively and reached a maximum on day 
1. It then decreased, but remained significantly elevated 
on day 3 (Fig. 2). The frequency of LAG-3+CD4+ T cells 
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also increased and was slightly higher than the preopera-
tive level on day 3 (Fig. 3; P = 0.098). The frequency of 
PD-1+CD8+ T cells significantly increased and reached a 
maximum on day 7 after surgery before returning to the 
preoperative level on day 30 (Fig. 4). The frequency of 
LAG-3+CD8+ T cells was slightly higher on day 7 than 
the preoperative level (Fig. 5; P = 0.077).
 Because increases in both PD-1 and LAG-3 expres-
sion on CD4+ T cells were observed on day 3, the cor-
relation between PD-1 and LAG-3 expression on CD4+ 
T cells on day 3 was determined; a significant positive 
correlation was found (Fig. 6a; r = 0.39, P = 0.024). In-
creases in PD-1 and LAG-3 expression on CD8+ T cells 
were observed on day 7 and a significant positive corre-
lation was found on day 7 (Fig. 6b; r = 0.37, P = 0.033).   
  
Fig. 6. Correlation between PD-1 and LAG-3 expression on CD4+ (a) and CD8+ T cells (b).
Fig. 4. (a) The reaction of isotypic control to CD8+ T cells after 
surgery by FACS. (b) Representative results for PD-1 on CD8+ 
T cells in peripheral blood obtained from gastric cancer patients 
after surgery by FACS. (c) Changes in PD-1 expression on CD8+ 
T cells after surgery. POD, postoperative day; Pre-op, preopera-
tion.
Fig. 5. (a) The reaction of isotypic control to CD8+ T cells after 
surgery by FACS. (b) Representative results for LAG-3 on CD8+ 
T cells in peripheral blood obtained from gastric cancer patients 
after surgery by FACS. (c) Changes in LAG-3 expression on CD8+ 
T cells after surgery. POD, postoperative day; Pre-op, preopera-
tion.
DISCUSSION
During the perioperative and postoperative periods, a 
complex biological response takes place in response 
to surgical stress. This response is intended to restore 
homeostasis as one aspect of host defenses against surgi-
cal stress and is thus a very important response for the 
host. However, surgical stress induces suppression of 
cell-mediated immunity that is harmful to patients with 
cancer who have undergone surgery because it may di-
minish their ability to prevent postoperative infections. 
Importantly, surgical stress-induced suppression of cell-
mediated immunity may also place a patient at higher 
risk for tumor recurrence. T cells are a critical compo-
nent of cellular immunity and in the current study the 
absolute number of lymphocytes significantly decreased 
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after surgery in gastric cancer patients. There was evi-
dence of impaired cell-mediated immunity after opera-
tion, consistent with a previous report by Wichmann et 
al.5
 Regulatory pathways that limit the immune response 
of T cells are becoming increasingly well characterized. 
For instance, cosignaling molecules are cell-surface 
glycoproteins that can direct, modulate and fine-tune 
T cell receptor signals. On the basis of their functional 
outcome, cosignaling molecules can be divided into co-
stimulators and coinhibitors, which promote or suppress 
T cell activation, respectively. Through expression at the 
appropriate time and location, cosignaling molecules 
positively and negatively control the priming, growth, 
differentiation and functional maturation of a T cell re-
sponse.26 PD-1 and LAG-3 are coinhibitors. In the cur-
rent study, we determined the PD-1 and LAG-3 expres-
sion on both CD4+ and CD8+ T cells to demonstrate the 
detailed mechanisms responsible for the impaired cell 
immunity observed after surgery in gastric cancer pa-
tients. The expression of both PD-1 and LAG-3 was up-
regulated on CD4+ and CD8+ T cells after surgery. We 
have previously reported that PD-1 expression on CD4+ 
and CD8+ T cells was increased compared with normal 
controls in gastric cancer patients.27 Furthermore, PD-
1-positive CD4+ and CD8+ T cells produced significantly 
less interferon-gamma than PD-1-negative CD4+ and 
CD8+ T cells, indicating that upregulation of PD-1 on 
both CD4+ and CD8+ T cells may be, in part, responsible 
for the immune evasion observed in gastric cancer pa-
tients.27 The current results indicate that surgical stress 
induces further suppression of cell-mediated immunity 
in the postoperative period. Although increases in LAG-
3 expression observed in the current study were less than 
those for PD-1, LAG-3 expression tended to be higher 
than preoperative levels during the postoperative period. 
Turnis et al. demonstrated the coexpression of LAG-3 
and PD-1 by TILs.28, 29 This coexpression is enriched in 
lymphocytes infiltrating certain human cancers and cor-
relates with impaired CD8+ effector function. Woo et al. 
demonstrated that LAG-3 and PD-1 synergistically regu-
late T cell function to promote tumoral immune escape 
in mice.30 Furthermore, Okazaki et al. showed that PD-1 
and LAG-3 act synergistically to prevent autoimmunity 
in mice.31 These data show that synergistic action of 
both LAG-3 and PD-1 plays an extremely important role 
in regulating T cell function in various situations. In 
fact, there were significant positive correlations between 
PD-1 and LAG-3 expression in both CD4+ and CD8+ T 
cells in the current study.
 Recently, regulatory pathways that limit the im-
mune response to cancer have attracted considerable 
attention as an important target for immunotherapy. 
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) 
is one of the representative molecules that downregu-
lates T cell activation pathways.32 Ipilimumab, a fully 
human monoclonal antibody that blocks CTLA-4, has 
recently been shown to promote antitumor immunity 
and improve overall survival in patients with previously 
treated metastatic melanoma.33 Furthermore, it has been 
demonstrated that treatment with the anti-PD-1 antibody 
pembrolizumab (lambrolizumab) resulted in a high rate 
of sustained tumor regression, with mainly grade 1 or 
2 adverse events, in patients with advanced melanoma, 
including those who had disease progression during 
previous treatment with ipilimumab.34 These results 
clearly indicate that immunotherapy targeting immune 
checkpoint molecules is effective for cancer therapy. 
The suppression of cell-medicated immunity induced 
by gastric cancer surgery puts patients at high risk of 
recurrence. However, adjuvant chemotherapy cannot be 
given immediately after surgery to prevent recurrence 
because it is likely that early initiation of chemotherapy 
increases the risk of complications. In contrast, im-
munotherapy targeting immune checkpoint molecules 
might be well suited to this situation. Because PD-1 and 
LAG-3 expression on both CD4+ and CD8+ T cells is 
upregulated after gastric cancer surgery, immunotherapy 
targeting PD-1 and LAG-3 may be effective in the treat-
ment of gastric cancer. However, the correlation between 
overexpression of PD-1 and LAG-3 on lymphocytes and 
dysfunction of cell-mediated immunity in postoperative 
situation has not been determined in the current study. 
Further investigations are urgently required to show the 
possibility of treatment targeting PD-1 and LAG-3 for 
the treatment of gastric cancer patients after surgery.
 In conclusion, PD-1 and LAG-3 expression on both 
CD4+ and CD8+ T cells was upregulated and might be 
related to impaired cell-mediated immunity after sur-
gery for gastric cancer.
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